Michael Heuer - Roche Holding CEO

RHHVF Stock  USD 256.16  3.76  1.49%   

CEO

Dr. Michael Heuer is no longer a Member of the Corporationrationrate Executive Committee, Interim Chief Executive Officer Roche Diagnostics at Roche Holding Ltd effective July 31st, 2019. He Heuer joined Boehringer Mannheim in 1983 and was appointed to his current position in 2018. Following the acquisition of Boehringer Mannheim by Roche in 1998, he held various management positions in sales, marketing and product development in Germany, Austria and the United States before being appointed Head of Roche Near Patient Testing business unit. Prior to his current role, he was Head of Diagnostics Europe, Middle East, Africa and Latin America region. Michael Heuer holds a PhD in Chemistry from the University of Kiel. since 2018.
Age 64
Tenure 6 years
Professional MarksPh.D
Phone41 61 688 11 11
Webhttps://www.roche.com

Roche Holding Management Efficiency

The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 16.08 B in total debt with debt to equity ratio (D/E) of 1.0, which is about average as compared to similar companies. Roche Holding AG has a current ratio of 1.09, suggesting that it may have difficulties to pay its financial obligations in time and when they become due. Debt can assist Roche Holding until it has trouble settling it off, either with new capital or with free cash flow. So, Roche Holding's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Roche Holding AG sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Roche to invest in growth at high rates of return. When we think about Roche Holding's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 14 records

CEO Age

Elizabeth BarrettNovartis AG ADR
56
Michael BallNovartis AG ADR
62
Osamu NagayamaRoche Holding
69
Bruno StriginiNovartis AG ADR
N/A
William AndersonRoche Holding
57
Severin SchwanRoche Holding
56
Paul HudsonNovartis AG ADR
51
Chris IlsleyNovartis AG ADR
N/A
Francesco BalestrieriNovartis AG ADR
N/A
PerOlof AttingerRoche Holding
58
Richard SaynorNovartis AG ADR
57
Jacob NaardenEli Lilly And
39
Pascal SoriotAstraZeneca PLC ADR
60
Joseph JimenezNovartis AG ADR
58
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company was founded in 1896 and is headquartered in Basel, Switzerland. Roche Hld operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 100920 people. Roche Holding AG [RHHVF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Roche Holding AG Leadership Team

Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
Barbara Schadler, Head Communications
Osamu Nagayama, Member of the Enlarged Corporate Executive Committee and Presidentident and CEO of Chugai
Michael Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development
Bruno Eschli, Head Relations
Silvia Ayyoubi, Head of Group HR
Sophie KornowskiBonnet, Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering
Thomas Schinecker, Chief Diagnostics
Beatrice Mauro, Non-Executive Director
Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources
William Anderson, Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals
Roland Diggelmann, Member of the Corporate Executive Committee, COO of the Division Roche Diagnostics
James Sabry, Member of the Enlarged Corporate Executive Committee, Global Head Pharma Partnering
Gottlieb Keller, General Counsel and Corporate Secretary
Urs Jaisli, Chief Compliance Officer
Daniel ODay, COO of Pharmaceuticals division
Claudia Bockstiegel, G Counsel
DeAnne Julius, Non-Executive Director
Johannes MD, Head Devel
Karl Mahler, Head of Investor Relations
Andre Hoffmann, Non-Executive Vice Chairman of the Board
John Reed, Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development
Claudia Dyckerhoff, Non-Executive Director
Fritz Gerber, Honorary Chairman of the Board
Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications
Julie Brown, Non-Executive Director
Richard Lifton, Non-Executive Director
Paul Bulcke, Non-Executive Director
Christoph Franz, Non-Executive Director
PerOlof Attinger, Secretary to the Corporate Executive Committee, Head CEO Office
Pascale Schmidt, Chief Officer
Pius Baschera, Non-Executive Director
Peter Voser, Non-Executive Director
Bernard Poussot, Non-Executive Director
John Bell, Non-Executive Director
Andreas Oeri, Non-Executive Director
Alan Hippe, CFO and IT Officer
William Pao, Member of the Enlarged Corporate Executive Committee, Head Roche Pharma Research & Early Development (pRED)
F Hoffmann, IR Contact Officer
Severin Schwan, CEO and Director
Anita Hauser, Non-Executive Director
Michael Heuer, Member of the Corporate Executive Committee, Interim CEO Roche Diagnostics

Roche Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Roche Holding in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Roche Holding's short interest history, or implied volatility extrapolated from Roche Holding options trading.

Currently Active Assets on Macroaxis

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Roche Holding AG. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in real.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Complementary Tools for Roche OTC Stock analysis

When running Roche Holding's price analysis, check to measure Roche Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roche Holding is operating at the current time. Most of Roche Holding's value examination focuses on studying past and present price action to predict the probability of Roche Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roche Holding's price. Additionally, you may evaluate how the addition of Roche Holding to your portfolios can decrease your overall portfolio volatility.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Please note, there is a significant difference between Roche Holding's value and its price as these two are different measures arrived at by different means. Investors typically determine if Roche Holding is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Roche Holding's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.